Literature DB >> 24822110

Infrequent ERBB2 mutations in Chinese patients with non-small cell lung cancer.

Shuidong Feng1, Hongyan Ling1, Hui Guo1, Lingling Tong1, Guobin Hu1, Li Liao1, Xueying Lv1, Hongzhuan Tan1, Yimou Wu1.   

Abstract

ERBB2 mutations have been reported to occur in a subset of patients with lung adenocarcinomas or lung squamous cell carcinomas for some ethnicities, but it is unclear for Chinese patients with lung squamous cell carcinomas up to now. We retrospectively evaluated the status of ERBB2 mutations in a large cross-sectional cohort of 212 Chinese patients with non-small cell lung cancer (NSCLC) diagnosed in several hospitals from southern China during a time period of 1.5 years by polymerase chain reaction (PCR)-based direct sequencing and PCR-single strand conformation polymorphism (PCR-SSCP) analysis. ERBB2 mutation was found in 1 of 49 lung adenocarcinomas (2.0%) and none in lung squamous cell carcinomas and lung adenosquamous carcinomas. It implies the occurrence of ERBB2 mutations is infrequent in Chinese patients with NSCLC, especially in lung squamous cell carcinomas.

Entities:  

Keywords:  ERBB2/HER2; molecular; mutation; non-small cell lung cancer (NSCLC)

Year:  2014        PMID: 24822110      PMCID: PMC4015026          DOI: 10.3978/j.issn.2072-1439.2014.03.20

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  13 in total

1.  Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.

Authors:  Chenguang Li; Yihua Sun; Rong Fang; Xiangkun Han; Xiaoyang Luo; Rui Wang; Yunjian Pan; Haichuan Hu; Yang Zhang; William Pao; Lei Shen; Hongbin Ji; Haiquan Chen
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

2.  HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Lynne Bemis; Marileila Varella-Garcia
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

3.  Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Authors:  Yang Zhang; Yihua Sun; Yunjian Pan; Chenguang Li; Lei Shen; Yuan Li; Xiaoyang Luo; Ting Ye; Rui Wang; Haichuan Hu; Hang Li; Lei Wang; William Pao; Haiquan Chen
Journal:  Clin Cancer Res       Date:  2012-02-08       Impact factor: 12.531

4.  EGFR and erbB2 mutation status in Japanese lung cancer patients.

Authors:  Hidefumi Sasaki; Shigeki Shimizu; Katsuhiko Endo; Minoru Takada; Masaaki Kawahara; Hisaichi Tanaka; Akihide Matsumura; Keiji Iuchi; Hiroshi Haneda; Eriko Suzuki; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  Int J Cancer       Date:  2006-01-01       Impact factor: 7.396

5.  Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.

Authors:  Kenji Tomizawa; Kenichi Suda; Ryoichi Onozato; Takayuki Kosaka; Hideki Endoh; Yoshitaka Sekido; Hisayuki Shigematsu; Hiroyuki Kuwano; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  Lung Cancer       Date:  2011-02-25       Impact factor: 5.705

6.  ERBB2 kinase domain mutation in the lung squamous cell carcinoma.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Suk Woo Nam; Won Sang Park; Young Pil Wang; Keon Hyun Jo; Seok Whan Moon; Sang Yong Song; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Cancer Lett       Date:  2005-07-18       Impact factor: 8.679

7.  EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.

Authors:  Toshihiko Yokoyama; Masashi Kondo; Yasuhiro Goto; Takayuki Fukui; Hiromu Yoshioka; Kohei Yokoi; Hirotaka Osada; Kazuyoshi Imaizumi; Yoshinori Hasegawa; Kaoru Shimokata; Yoshitaka Sekido
Journal:  Cancer Sci       Date:  2006-08       Impact factor: 6.716

8.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

Authors:  Hisayuki Shigematsu; Takao Takahashi; Masaharu Nomura; Kuntal Majmudar; Makoto Suzuki; Huei Lee; Ignacio I Wistuba; Kwun M Fong; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

9.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

10.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

View more
  1 in total

1.  Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma.

Authors:  Ling Shan; Tian Qiu; Yun Ling; Lei Guo; Bo Zheng; Bingning Wang; Wenbin Li; Lin Li; Jianming Ying
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.